


10/500895  
DT04 Rec'd PCT/PTO 07 JUL 2004

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claim 1 (original): A compound represented by Formula I:



I

or a pharmaceutically acceptable salt or hydrate thereof, wherein:

Ar is phenyl or naphthyl;

m = 0 or 1;

n = 0 or 1;

A is selected from the group consisting of:  $-\text{CO}_2\text{H}$ ,  $-\text{PO}_3\text{H}_2$ ,  $-\text{PO}_2\text{H}$ ,  $-\text{SO}_3\text{H}$ ,  $-\text{PO}(\text{C}_1\text{-3alkyl})\text{OH}$  and 1H-tetrazol-5-yl;

$\text{R}^1$  and  $\text{R}^2$  are each independently selected from the group consisting of: hydrogen, halo, hydroxy,  $-\text{CO}_2\text{H}$  and  $\text{C}_1\text{-4alkyl}$ , optionally substituted from one up to the maximum number of substitutable positions with halo;

$\text{R}^3$  is selected from the group consisting of: hydrogen and  $\text{C}_1\text{-4alkyl}$ , optionally substituted with from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo and hydroxy;

each  $\text{R}^4$  is independently selected from the group consisting of: halo,  $\text{C}_1\text{-4alkyl}$  and  $\text{C}_1\text{-3alkoxy}$ , said  $\text{C}_1\text{-4alkyl}$  and  $\text{C}_1\text{-3alkoxy}$  optionally substituted from one up to the maximum number of substitutable positions with halo,


C is selected from the group consisting of:

- (1) C<sub>1-8</sub>alkyl, C<sub>1-8</sub>alkoxy, -(C=O)-C<sub>1-6</sub>alkyl or -CHOH-C<sub>1-6</sub>alkyl, said C<sub>1-8</sub>alkyl, C<sub>1-8</sub>alkoxy, -(C=O)-C<sub>1-6</sub>alkyl and -CHOH-C<sub>1-6</sub>alkyl optionally substituted with phenyl, and
- (2) phenyl or HET, each optionally substituted with 1-3 substituents independently selected from the group consisting of: halo, phenyl, C<sub>1-4</sub>alkyl and C<sub>1-4</sub>alkoxy, said C<sub>1-4</sub>alkyl and C<sub>1-4</sub>alkoxy groups optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from halo and hydroxy, and said phenyl optionally substituted with 1 to 5 groups independently selected from the group consisting of: halo and C<sub>1-4</sub>alkyl, optionally substituted with 1-3 halo groups,

or C is not present;

when C is not present then B is selected from the group consisting of: phenyl, C<sub>5-16</sub>alkyl, C<sub>5-16</sub>alkenyl, C<sub>5-16</sub>alkynyl, -CHOH-C<sub>4-15</sub>alkyl, -CHOH-C<sub>4-15</sub>alkenyl, -CHOH-C<sub>4-15</sub>alkynyl, C<sub>4-15</sub>alkoxy, -O-C<sub>4-15</sub>alkenyl, -O-C<sub>4-15</sub>alkynyl, C<sub>4-15</sub>alkylthio, -S-C<sub>4-15</sub>alkenyl, -S-C<sub>4-15</sub>alkynyl, -CH<sub>2</sub>-C<sub>3-14</sub>alkoxy, -CH<sub>2</sub>-O-C<sub>3-14</sub>alkenyl, -CH<sub>2</sub>-O-C<sub>3-14</sub>alkynyl, -(C=O)-C<sub>4-15</sub>alkyl, -(C=O)-C<sub>4-15</sub>alkenyl, -(C=O)-C<sub>4-15</sub>alkynyl, -(C=O)-O-C<sub>3-14</sub>alkyl, -(C=O)-O-C<sub>3-14</sub>alkenyl, -(C=O)-O-C<sub>3-14</sub>alkynyl, -(C=O)-N(R<sup>6</sup>)(R<sup>7</sup>)-C<sub>3-14</sub>alkyl, -(C=O)-N(R<sup>6</sup>)(R<sup>7</sup>)-C<sub>3-14</sub>alkenyl, -(C=O)-N(R<sup>6</sup>)(R<sup>7</sup>)-C<sub>3-14</sub>alkynyl, -N(R<sup>6</sup>)(R<sup>7</sup>)-(C=O)-C<sub>3-14</sub>alkyl, -N(R<sup>6</sup>)(R<sup>7</sup>)-(C=O)-C<sub>3-14</sub>alkenyl and -N(R<sup>6</sup>)(R<sup>7</sup>)-(C=O)-C<sub>3-14</sub>alkynyl,

when C is phenyl or HET then B is selected from the group consisting of: C<sub>1-6</sub>alkyl, C<sub>1-5</sub>alkoxy, -(C=O)-C<sub>1-5</sub>alkyl, -(C=O)-O-C<sub>1-4</sub>alkyl, -(C=O)-N(R<sup>6</sup>)(R<sup>7</sup>)-C<sub>1-4</sub>alkyl, C<sub>1-3</sub>alkyl



, phenyl and HET, and

when C is C<sub>1-8</sub>alkyl, C<sub>1-8</sub>alkoxy, -(C=O)-C<sub>1-6</sub>alkyl or -CHOH-C<sub>1-6</sub>alkyl then B is phenyl; and

R<sup>6</sup> and R<sup>7</sup> are independently selected from the group consisting of: hydrogen, C<sub>1-9</sub>alkyl and -(CH<sub>2</sub>)<sub>p</sub>-phenyl, wherein p is 1 to 5 and phenyl is optionally substituted with 1-3 substituents independently selected from the group consisting of: C<sub>1-3</sub>alkyl and C<sub>1-3</sub>alkoxy, each optionally substituted with 1-3 halo groups.

Claim 2 (original): The compound according to Claim 1 wherein:

Ar is phenyl;

the group **-B-C** is attached to the phenyl ring at the 3- or 4-position;

**C** is phenyl or HET, each optionally substituted with 1-3 substituents independently selected from the group consisting of: halo, phenyl, C<sub>1-4</sub>alkyl and C<sub>1-4</sub>alkoxy, said C<sub>1-4</sub>alkyl and C<sub>1-4</sub>alkoxy groups optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from halo and hydroxy, and said phenyl optionally substituted with 1 to 5 groups independently selected from the group consisting of: halo and C<sub>1-4</sub>alkyl, optionally substituted with 1-3 halo groups,


or **C** is not present;

when **C** is not present then **B** is selected from the group consisting of: C<sub>7-12</sub>alkyl, C<sub>7-12</sub>alkenyl, C<sub>7-12</sub>alkynyl, C<sub>6-11</sub>alkoxy, -O-C<sub>6-11</sub>alkenyl, -O-C<sub>6-11</sub>alkynyl, -(C=O)-C<sub>6-11</sub>alkyl, -(C=O)-C<sub>6-11</sub>alkenyl, -(C=O)-C<sub>6-11</sub>alkynyl, -(C=O)-O-C<sub>5-10</sub>alkyl, -(C=O)-O-C<sub>5-10</sub>alkenyl, and -(C=O)-O-C<sub>5-10</sub>alkynyl and **C** is not present;

and

when **C** is phenyl or HET then **B** is selected from the group consisting of C<sub>1-5</sub>alkyl, C<sub>1-4</sub>alkoxy, -(C=O)-C<sub>1-4</sub>alkyl, -(C=O)-O-C<sub>1-3</sub>alkyl, phenyl and HET.

Claim 3 (original): The compound according to Claim 1 wherein HET is selected from the group consisting of:



Claim 4 (original): The compound according to Claim 1 wherein m is 0.

Claim 5 (original): The compound according to Claim 1 wherein m is 1.

Claim 6 (original): The compound according to Claim 1 wherein n is 0.


Claim 7 (original): The compound according to Claim 1 wherein n is 1.

Claim 8 (original): The compound according to Claim 1 wherein **B** is selected from the group consisting of: C<sub>7-12</sub>alkyl, C<sub>7-12</sub>alkenyl, C<sub>7-12</sub>alkynyl, C<sub>6-11</sub>alkoxy, -O-C<sub>6-11</sub>alkenyl, -O-C<sub>6-11</sub>alkynyl, -(C=O)-C<sub>6-11</sub>alkyl, -(C=O)-C<sub>6-11</sub>alkenyl, -(C=O)-C<sub>6-11</sub>alkynyl, -(C=O)-O-C<sub>5-10</sub>alkyl, -(C=O)-O-C<sub>5-10</sub>alkenyl, and -(C=O)-O-C<sub>5-10</sub>alkynyl and **C** is not present.

Claim 9 (original): The compound according to Claim 1 wherein:

**B** is methoxy and **C** is HET substituted with phenyl and C<sub>1-4</sub>alkyl, said C<sub>1-4</sub>alkyl optionally substituted from one up to the maximum number of substitutable positions with halo, and said phenyl, optionally substituted with 1 to 5 substituents independently selected from the group consisting of: halo and C<sub>1-4</sub>alkyl, optionally substituted with 1-3 halo groups.

Claim 10 (original): The compound according to Claim 8 wherein **C** is selected from the group consisting of:




Claim 11 (original): The compound according to Claim 9 wherein **C** is thiophene or furan.

Claim 12 (original): The compound according to Claim 1 wherein:

**B** is methoxy and **C** is HET.

Claim 13 (original): The compound according to Claim 12 wherein **C** is selected from the group consisting of:



Claim 14 (original): The compound according to Claim 13 wherein **C** is benzothiophene or benzofuran.

Claim 15 (original): The compound according to Claim 1 wherein:


**B** is methoxy and **C** is phenyl substituted with two  $C_{1-4}$ alkyl groups, said  $C_{1-4}$ alkyl optionally substituted from one up to the maximum number of substitutable positions with halo.

Claim 16 (original): The compound according to Claim 1 wherein:

**B** is HET and **C** is HET substituted with phenyl and  $C_{1-4}$ alkyl, said  $C_{1-4}$ alkyl optionally substituted from one up to the maximum number of substitutable positions with halo, and said phenyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of: halo,  $C_{1-4}$ alkyl, optionally substituted with 1-3 halo groups.

Claim 17 (original): The compound according to Claim 16 wherein **B** is 1,2,4-oxadiazole.

Claim 18 (original): The compound according to Claim 17 wherein **C** is selected from the group consisting of:




Claim 19 (original): The compound according to Claim 18 wherein **C** is thiophene or furan.


Claim 20 (original): The compound according to Claim 1 wherein  $m = 0$  and **A** is  $-\text{CO}_2\text{H}$ .


Claim 21 (original): The compound according to Claim 20 wherein  $\text{R}^1$ ,  $\text{R}^2$  and  $\text{R}^3$  are hydrogen.

Claim 22 (original): The compound according to Claim 2 wherein the group **-B-C** is attached to the phenyl ring at the 4-position.


Claim 23 (original): The compound according to Claim 1 selected from the following table:




























Claim 24 (original): A compound represented by Formula II



II

or a pharmaceutically acceptable salt or hydrate thereof, wherein:

$n = 0$  or  $1$ ;

$R^3$  is selected from the group consisting of: hydrogen and  $C_{1-4}$ alkyl, optionally substituted with from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo and hydroxy;


each  $R^4$  is independently selected from the group consisting of: halo,  $C_{1-4}$ alkyl and  $C_{1-3}$ alkoxy, said  $C_{1-4}$ alkyl and  $C_{1-3}$ alkoxy optionally substituted from one up to the maximum number of substitutable positions with halo.








Claim 25 (original): The compound according to Claim 24 wherein  $n$  is 0.

Claim 26 (original): The compound according to Claim 24 wherein  $n$  is 1.


Claim 27 (original): The compound according to Claim 24 wherein  $R^3$  is hydrogen.

Claim 28 (original): The compound according to Claim 24 selected from the following table:



Claim 29 (original): A compound represented by Formula III



III

or a pharmaceutically acceptable salt or hydrate thereof, wherein:

n = 0 or 1;

R<sup>3</sup> is selected from the group consisting of: hydrogen and C<sub>1</sub>-4alkyl, optionally substituted with from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo and hydroxy;


each R<sup>4</sup> is independently selected from the group consisting of: halo, C<sub>1</sub>-4alkyl and C<sub>1</sub>-3alkoxy, said C<sub>1</sub>-4alkyl and C<sub>1</sub>-3alkoxy optionally substituted from one up to the maximum number of substitutable positions with halo.

Claim 30 (original): The compound according to Claim 29 wherein n is 0.

Claim 31 (original): The compound according to Claim 29 wherein n is 1.

Claim 32 (original): The compound according to Claim 29 wherein R<sup>3</sup> is hydrogen.

Claim 33 (original): The compound according to Claim 29 selected from the following table:



Claim 34 (original): A method of treating an immunoregulatory abnormality in a mammalian patient in need of such treatment comprising administering to said patient a compound in accordance with Claim 1 in an amount that is effective for treating said immunoregulatory abnormality.

Claims 35- 46 (canceled)

Claim 47 (original): A pharmaceutical composition comprised of a compound in accordance with Claim 1 in combination with a pharmaceutically acceptable carrier.